PT Kalbe Farma Tbk : Company Update Q3 2024 Unaudited Results (30 October 2024)

About this update from Pt Kalbe Farma Tbk

Company Update 9M24 PT Kalbe Farma Tbk October 2024 Table of Content • Key Updates 04 • Key Business Strategies 07 • Financial Overview 24 • Appendix 1 31 • Appendix 2 38 Key Updates Business Strategies Positive Net Sales Growth Post-Pandemic Prescription Pharmaceuticals Building Participation in Dominant Specialty Portfolio National Health Insurance Market Leader Steadily growing specialty Consistent growth Leading with 13% category with in E-Catalog market share expanding innovative portfolio, supported by local manufacturing Driving Future Growth through Strategic Collaborations Prescription Pharmaceuticals Sustaining Business Expansion through Strategic Partnerships Livzon Pharma Indonesia Shareholder Agreement Signing Jul 2024 To locally manufacture more advanced pharmaceuticals ingredients for the export market, by looking at the potential for use in the domestic market in the future Exclusive Collaboration signing May 2024 To increase market penetration and the availability of Kalbe products in the SEA, particularly Thailand JV establishment Dec 2022 To secure raw materials, open potential future expansion in China, and reduce dependence on the use of the US dollar Completion Dec 2022 To strengthen portfolio in focused therapeutic classes (Diabetic and Cardiovascular) and access to new category such as vaccines Oncology Biological-based Other Complete product range in all segments covering licensed, branded and unbranded generics Attention : This is an excerpt of the original content. To continue reading it, access the original document here .

View stock analysis, news, and events for Pt Kalbe Farma Tbk